Skip to main content

Table 1 Patient and operative characteristics

From: Clinical study of a new skin antiseptic olanexidine gluconate in gastrointestinal cancer surgery

Patient characteristics OLG group (n = 223) Control group (n = 58) P value
Mean age (range) 73.2 ± 10.7 73.9 ± 10.2 0.853
Gender 0.455
 M 133 (59.6%) 31 (53.4%)  
 F 90 (40.4%) 27 (46.6%)  
Mean BMI ± SD 22.1 ± 3.5 22.4 ± 3.7 0.6
Diabetes mellitus (%) 66 (29.6%) 19 (32.8%) 0.634
Alb 3.89 ± 0.52 3.86 ± 0.57 0.752
Respiratory disease 39 (17.5%) 8 (13.8%) 0.56
Anticoagulant 41 (16.7%) 10 (17.2%) 1
Primary lesion 1
 Stomach 66 (29.6%) 17 (29.3%)  
 Colon 157 (70.4%) 41 (70.7%)  
ASA 0.495
 1.2 171 (76.7%) 42 (72.4%)  
 3 52 (23.3%) 16 (27.6%)  
Mean operation time ± SD 303.0 ± 108.8 297.2 ± 134.9 0.732
Bleeding (ml) 130.4 ± 244.5 133.3 ± 152.8 0.932
Approach 0.000171
 Open 91 (43.8%) 42 (72.4%)  
 Laparoscopy 117 (56.2%) 16 (27.6%)  
 Transfusion 5 (2.3%) 1 (1.7%) 1
Stage 0.641
 0, I, II 150 (67.3%) 37 (63.8%)  
 III, IV 73 (32.7%) 21 (36.2%)  
Leakage 4 (1.8%) 5 (8.6%) 0.0205
Complication except SSI 51 (22.9%) 18 (31.0%) 0.232
Postoperative length of hospital stay (days) 15.8 ± 10.4 20.0 ± 15.8 0.0136
Adverse skin reaction (all) 4 (1.8%) 3 (5.2%) 0.157
 Skin irritation 2 (0.9%) 0 (0%) 1
 Erythema 3 (1.3%) 3 (5.2%) 0.105
 Pruritus 1 (0.4%) 1 (1.7%) 0.371
  1. Control group: PVP-I group